Comparative bioavailability of a premixed, ready-to-use formulation of intravenous amiodarone with traditional admixture in healthy subjects.

Autor: Cushing DJ; Prism Pharmaceuticals, King of Prussia, PennsylvaniaPrism Pharmaceuticals, Kennett Square, Pennsylvania., Adams MP, Cooper WD, Agha B, Souney PF
Jazyk: angličtina
Zdroj: Journal of clinical pharmacology [J Clin Pharmacol] 2012 Feb; Vol. 52 (2), pp. 214-21.
DOI: 10.1177/0091270010395938
Abstrakt: Intravenous amiodarone is an effective agent for the treatment of recurrent ventricular fibrillation and hemodynamically unstable ventricular tachycardia. PM101 Premixed Injection is a new formulation of intravenous amiodarone that uses a cyclodextrin to maintain amiodarone in the aqueous phase. Eighty-eight subjects were enrolled in this randomized, single-blind, crossover, bioequivalence clinical study and were treated with single doses (150 mg) of PM101 Premixed Injection and intravenous amiodarone separated by a washout period of at least 42 days. Venous blood samples were taken periodically during the first 72 hours after dosing to determine standard pharmacokinetic parameters. The geometric ratio of the area under the concentration-time curve for time 0-72 hours (AUC0-72hr ) for amiodarone was 0.96 (95% confidence interval [CI], 0.94-0.99). The geometric ratio of the maximum concentration (Cmax ) for amiodarone was 0.87 (95% CI, 0.84-0.91). Because these ratios and their CI fell between the limits of 0.8 and 1.25, bioequivalence of these 2 formulations was established. No safety concerns unique to the PM101 Premixed Injection, ready-to-use formulation were identified.
(2012 American College of Clinical Pharmacology.)
Databáze: MEDLINE
Externí odkaz: